204 related articles for article (PubMed ID: 15044850)
1. Use of methotrexate-based peptide substrates to characterize the substrate specificity of prostate-specific membrane antigen (PSMA).
Mhaka A; Gady AM; Rosen DM; Lo KM; Gillies SD; Denmeade SR
Cancer Biol Ther; 2004 Jun; 3(6):551-8. PubMed ID: 15044850
[TBL] [Abstract][Full Text] [Related]
2. Targeting prostate-specific membrane antigen in cancer therapy: can molecular medicine be brought to the surface?
Leach F
Cancer Biol Ther; 2004 Jun; 3(6):559-60. PubMed ID: 15153802
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific membrane antigen (PSMA)-mediated laminin proteolysis generates a pro-angiogenic peptide.
Conway RE; Rojas C; Alt J; Nováková Z; Richardson SM; Rodrick TC; Fuentes JL; Richardson NH; Attalla J; Stewart S; Fahmy B; Barinka C; Ghosh M; Shapiro LH; Slusher BS
Angiogenesis; 2016 Oct; 19(4):487-500. PubMed ID: 27387982
[TBL] [Abstract][Full Text] [Related]
4. A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity.
Aggarwal S; Singh P; Topaloglu O; Isaacs JT; Denmeade SR
Cancer Res; 2006 Sep; 66(18):9171-7. PubMed ID: 16982760
[TBL] [Abstract][Full Text] [Related]
5. PSMA-targeted stably linked "dendrimer-glutamate urea-methotrexate" as a prostate cancer therapeutic.
Huang B; Otis J; Joice M; Kotlyar A; Thomas TP
Biomacromolecules; 2014 Mar; 15(3):915-23. PubMed ID: 24392665
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells.
Pinto JT; Suffoletto BP; Berzin TM; Qiao CH; Lin S; Tong WP; May F; Mukherjee B; Heston WD
Clin Cancer Res; 1996 Sep; 2(9):1445-51. PubMed ID: 9816319
[TBL] [Abstract][Full Text] [Related]
7. Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid.
Yao V; Berkman CE; Choi JK; O'Keefe DS; Bacich DJ
Prostate; 2010 Feb; 70(3):305-16. PubMed ID: 19830782
[TBL] [Abstract][Full Text] [Related]
8. [Advances in prostate-specific membrane antigen-mediated antitumor drugs].
Lü QZ; Yang JC; Wang YJ
Yao Xue Xue Bao; 2016 Feb; 51(2):234-40. PubMed ID: 29856576
[TBL] [Abstract][Full Text] [Related]
9. PSMA-Oriented Target Delivery of Novel Anticancer Prodrugs: Design, Synthesis, and Biological Evaluations of Oligopeptide-Camptothecin Conjugates.
Xu B; Zhou F; Yan MM; Cai DS; Guo WB; Yang YQ; Jia XH; Zhang WX; Li T; Ma T; Wang PL; Lei HM
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347770
[TBL] [Abstract][Full Text] [Related]
10. In vitro targeted killing of prostate tumor cells by a synthetic amoebapore helix 3 peptide modified with two gamma-linked glutamate residues at the COOH terminus.
Warren P; Li L; Song W; Holle E; Wei Y; Wagner T; Yu X
Cancer Res; 2001 Sep; 61(18):6783-7. PubMed ID: 11559551
[TBL] [Abstract][Full Text] [Related]
11. A ROS-responsive polymeric prodrug nanosystem with self-amplified drug release for PSMA (-) prostate cancer specific therapy.
Wang Y; Zhang Y; Ru Z; Song W; Chen L; Ma H; Sun L
J Nanobiotechnology; 2019 Aug; 17(1):91. PubMed ID: 31451114
[TBL] [Abstract][Full Text] [Related]
12. PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer.
Flores O; Santra S; Kaittanis C; Bassiouni R; Khaled AS; Khaled AR; Grimm J; Perez JM
Theranostics; 2017; 7(9):2477-2494. PubMed ID: 28744329
[TBL] [Abstract][Full Text] [Related]
13. Disulfide-constrained peptides that bind to the extracellular portion of the prostate-specific membrane antigen.
Lupold SE; Rodriguez R
Mol Cancer Ther; 2004 May; 3(5):597-603. PubMed ID: 15141017
[TBL] [Abstract][Full Text] [Related]
14. Impact of short-term Dutasteride treatment on prostate-specific membrane antigen expression in a mouse xenograft model.
Kranzbühler B; Sousa R; Prause L; Burger IA; Rupp NJ; Sulser T; Salemi S; Eberli D
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1418. PubMed ID: 34008909
[TBL] [Abstract][Full Text] [Related]
15. Glycoforms of human prostate-specific membrane antigen (PSMA) in human cells and prostate tissue.
Yuan W; Liu B; Sanda M; Wei R; Benicky J; Novakova Z; Barinka C; Goldman R
Prostate; 2022 Jan; 82(1):132-144. PubMed ID: 34662441
[TBL] [Abstract][Full Text] [Related]
16. Effect of carbohydrate moieties on the folate hydrolysis activity of the prostate specific membrane antigen.
Ghosh A; Heston WD
Prostate; 2003 Oct; 57(2):140-51. PubMed ID: 12949938
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.
Liu C; Hasegawa K; Russell SJ; Sadelain M; Peng KW
Prostate; 2009 Jul; 69(10):1128-41. PubMed ID: 19367568
[TBL] [Abstract][Full Text] [Related]
18. GCPII imaging and cancer.
Foss CA; Mease RC; Cho SY; Kim HJ; Pomper MG
Curr Med Chem; 2012; 19(9):1346-59. PubMed ID: 22304713
[TBL] [Abstract][Full Text] [Related]
19. Cloning and characterization of canine prostate-specific membrane antigen.
Schmidt S; Fracasso G; Colombatti M; Naim HY
Prostate; 2013 May; 73(6):642-50. PubMed ID: 23359458
[TBL] [Abstract][Full Text] [Related]
20. New alternatively spliced variant of prostate-specific membrane antigen PSM-E suppresses the proliferation, migration and invasiveness of prostate cancer cells.
Cao KY; Xu L; Zhang DM; Zhang XM; Zhang T; He X; Wang Z; Feng FS; Qiu SP; Shen GX
Int J Oncol; 2012 Jun; 40(6):1977-85. PubMed ID: 22322627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
